AN - 2690，一种用于局部治疗甲癣的新型抗真菌药物。
AN-2690, a novel antifungal for the topical treatment of onychomycosis.
作者信息
Barak Orr, Loo Daniel S
机构信息
Tufts-New England Medical Center, Department of Dermatology, 750 Washington Street, Boston, MA 02111, USA.
出版信息
Curr Opin Investig Drugs. 2007 Aug;8(8):662-8.
PMID:17668368
Abstract
Schering-Plough Corp, under license from Anacor Pharmaceuticals Inc, is developing AN-2690, an antifungal agent with activity against Trichophyton species, in a topical solution formulation, for the potential treatment of onychomycosis. Phase II and IIb trials with AN-2690 are underway.
摘要
先灵葆雅公司根据Anacor制药公司的许可，正在开发一种名为AN - 2690的抗真菌剂，其对毛癣菌属具有活性，剂型为外用溶液，用于潜在治疗甲癣。目前正在进行AN - 2690的II期和IIb期试验。
相似文献
1
AN-2690, a novel antifungal for the topical treatment of onychomycosis.
Curr Opin Investig Drugs. 2007 Aug;8(8):662-8.
2
Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis.
J Med Chem. 2006 Jul 27;49(15):4447-50. doi: 10.1021/jm0603724.
3
Potential role of tavaborole for the treatment of onychomycosis.
Future Microbiol. 2014;9(11):1243-50. doi: 10.2217/fmb.14.76.
4
Tavaborole 5% solution for onychomycosis.
Skinmed. 2015 Jan-Feb;13(1):55-8.
5
In vitro efficacy of tavaborole topical solution, 5% after penetration through nail polish on ex vivo human fingernails.
J Dermatolog Treat. 2018 Sep;29(6):633-636. doi: 10.1080/09546634.2017.1422078. Epub 2018 Jan 10.
6
Topical Antifungals for Treatment of Onychomycosis.
Am Fam Physician. 2016 Nov 1;94(9):734.
7
Tavaborole: first global approval.
Drugs. 2014 Sep;74(13):1555-8. doi: 10.1007/s40265-014-0276-7.
8
Tavaborole 5% Solution: A Novel Topical Treatment for Toenail Onychomycosis.
Skin Therapy Lett. 2015 Nov;20(6):6-9.
9
Spotlight on tavaborole for the treatment of onychomycosis.
Drug Des Devel Ther. 2015 Nov 20;9:6185-90. doi: 10.2147/DDDT.S81944. eCollection 2015.
10
Tavaborole (AN-2690) for the treatment of onychomycosis of the toenail in adults.
Expert Rev Anti Infect Ther. 2014 Jul;12(7):735-42. doi: 10.1586/14787210.2014.915738. Epub 2014 Jun 4.
引用本文的文献
1
Biosynthesis and Chemical Synthesis of Albomycin Nucleoside Antibiotics.
Antibiotics (Basel). 2022 Mar 24;11(4):438. doi: 10.3390/antibiotics11040438.
2
Identification of a potent benzoxaborole drug candidate for treating cryptosporidiosis.
Nat Commun. 2019 Jun 27;10(1):2816. doi: 10.1038/s41467-019-10687-y.
3
Spotlight on tavaborole for the treatment of onychomycosis.
Drug Des Devel Ther. 2015 Nov 20;9:6185-90. doi: 10.2147/DDDT.S81944. eCollection 2015.
4
Analogs of natural aminoacyl-tRNA synthetase inhibitors clear malaria in vivo.
Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):E5508-17. doi: 10.1073/pnas.1405994111. Epub 2014 Dec 8.
5
Discovery of novel orally bioavailable oxaborole 6-carboxamides that demonstrate cure in a murine model of late-stage central nervous system african trypanosomiasis.
Antimicrob Agents Chemother. 2010 Oct;54(10):4379-88. doi: 10.1128/AAC.00498-10. Epub 2010 Jul 26.
Zotero 插件